Comparability of Mixed IC50 Data - A Statistical Analysis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kalliokoski, Tuomo ^a   Kramer, Christian ^a   Vulpetti, Anna ^a   Gedeck, Peter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); IC 50; MATHEMATICAL COMPUTING; MOLECULAR WEIGHT; NORMAL DISTRIBUTION; PARTITION COEFFICIENT; PROTEIN DATABASE; REDUNDANCY ANALYSIS; SAMPLING ERROR; SIGNAL NOISE RATIO; STATISTICAL ANALYSIS;

INHIBITORY CONCENTRATION 50; MODELS, STATISTICAL; MODELS, THEORETICAL;

EID: 84876174816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061007     Document Type: Article

References (19)

1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2011) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-D1107.
2. Hu Y, Bajorath J, (2012) Growth of Ligand-Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity. J Chem Inf Model 52: 2550-2558.
3. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL, (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
4. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
5. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, et al. (2007) Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure. ChemMedChem 2: 861-873.
6. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, et al. (2012) Automated design of ligands to polypharmacological profiles. Nature 492: 215-220.
7. Schürer SC, Muskal SM, (2013) Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets. J Chem Inf Model. 53: 27-38.
8. Kramer C, Beck B, Kriegl JM, Clark T, (2008) A Composite Model for hERG Blockade. ChemMedChem 3: 254-265.
9. Kirchmair J, Williamson MJ, Tyzack JD, Tan L, Bond PJ, et al. (2012) Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms. J Chem Inf Model 52: 617-648.
10. McCarren P, Bebernitz GR, Gedeck P, Glowienke S, Grondine MS, et al. (2011) Avoidance of the Ames test liability for aryl-amines via computation. Bioorg Med Chem 19: 3173-3182.
11. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
12. Zdrazil B, Pinto M, Vasanthanathan P, Williams AJ, Balderud LZ, et al. (2012) Annotating Human P-Glycoprotein Bioassay Data. Mol Inform 31: 599-609.
13. Kramer C, Kalliokoski T, Gedeck P, Vulpetti A, (2012) The Experimental Uncertainty of Heterogeneous Public Ki Data. J Med Chem 55: 5165-5173.
14. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK, (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35: D198-D201.
15. Team RC (2012) R: A Language and Environment for Statistical Computing. Vienna, Austria. Available: http://www.R-project.org.
16. Sahoo PK, Behera P, (2010) Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors. Eur J Med Chem 45: 909-914.
17. Kramer C, Lewis R, (2012) QSARs, data and error in the modern age of drug discovery. Curr Top Med Chem 12: 1896-1902.
18. Dunbar JB, Smith RD, Yang C-Y, Ung PM-U, Lexa KW, et al. (2011) CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes. J Chem Inf Model 51: 2036-2046.
19. Smith RD, Dunbar JB, Ung PM-U, Esposito EX, Yang C-Y, et al. (2011) CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions. J Chem Inf Model 51: 2115-2131.